Shandong Boan Biotechnology Co (FRA:UJ9) LT-Debt-to-Total-Asset : 0.10 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Shandong Boan Biotechnology Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Shandong Boan Biotechnology Co's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.10.

Shandong Boan Biotechnology Co's long-term debt to total assets ratio increased from Dec. 2022 (0.10) to Dec. 2023 (0.10). It may suggest that Shandong Boan Biotechnology Co is progressively becoming more dependent on debt to grow their business.

Shandong Boan Biotechnology Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Shandong Boan Biotechnology Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shandong Boan Biotechnology Co LT-Debt-to-Total-Asset Chart

Shandong Boan Biotechnology Co Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

0.01

0.12

0.10

Shandong Boan Biotechnology Co Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial			0.12	0.11	0.10	0.09	0.10

Shandong Boan Biotechnology Co LT-Debt-to-Total-Asset Calculation

Shandong Boan Biotechnology Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	30.116	/	298.387
	=	0.10

Shandong Boan Biotechnology Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	30.116	/	298.387
	=	0.10

Shandong Boan Biotechnology Co (FRA:UJ9) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Shandong Boan Biotechnology Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Shandong Boan Biotechnology Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Shandong Boan Biotechnology Co (FRA:UJ9) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shandong Boan Biotechnology Co Ltd (FRA:UJ9) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

06955:Hong Kong

Address

No. 39 Keji Avenue, High-Tech Industrial Development Zone, Shandong Province, Yantai, CHN

Website

https://www.boan-bio.com

Shandong Boan Biotechnology Co Ltd is a fully integrated biopharmaceutical company. The company is engaged in the development, manufacture, and commercialization of high-quality biologics in China and around the world. It focuses on areas such as oncology, metabolism, autoimmunity, and ophthalmology. Geographically company's revenue is generated from customers located in Mainland China.

Shandong Boan Biotechnology Co (FRA:UJ9) Headlines

No Headlines